Evidence map›Paper›PMID 28962610›Full record

ArticleBMC public health2017

Assessment of the HBV vaccine response in a group of HIV-infected children in Morocco.

Houda Haban, Soumia Benchekroun, Mina Sadeq, Abdelaziz Benjouad, Said Amzazi, Hicham Oumzil, Elmir Elharti

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC public health, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Immunological Considerations forFrontiers in immunology · 2021
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Houda HabanNational Reference Laboratory for HIV, Department of Virology, National Institute of Hygiene, Rabat, Morocco.
Soumia BenchekrounPediatric Infectious Disease Clinic, Ibn Sina University Hospital, Rabat, Morocco.
Mina SadeqEnvironmental Epidemiology Unit, National Institute of Hygiene, Rabat, Morocco.
Abdelaziz BenjouadInternational University of Rabat, Salé, Morocco.
Said AmzaziImmunology-Biochemistry Laboratory, Faculty of Sciences, University Mohammed Vth, Rabat, Morocco.
Hicham OumzilNational Reference Laboratory for HIV, Department of Virology, National Institute of Hygiene, Rabat, Morocco.
Elmir ElhartiNational Reference Laboratory for HIV, Department of Virology, National Institute of Hygiene, Rabat, Morocco. elhartie@yahoo.fr.ORCID 0000-0003-3164-8689
Institut National d'Hygiène du Maroc · MAMohammed V University · MAInternational University of Rabat · MA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSince its development in the early 1980s, Hepatitis B virus (HBV) vaccine has been proven to be highly protective. However, its immunogenicity may be ineffective among HIV-infected children. In Morocco, HBV vaccine was introduced in 1999, and since then all infants, including vertically HIV-infected infants, have been following the vaccination schedule, implemented by the Moroccan ministry of health. An assessment of the immunization of these children is important to optimize efforts aimed at tackling Hepatitis B coinfection, within the country.

methodsForty-nine HIV-infected children (HIV group) and 112 HIV uninfected children (control group) were enrolled in this study. Samples were tested by Elisa (Monolisa Anti-HBs, Biorad) to quantify the anti-HBs antibodies. The % of lymphocyte subsets i.e. CD4+ T cells, CD8+ T cells, B cells, and NK, was determined by flow cytometry, using CellQuest Pro software (Becton-Dickinson), and for HIV group, HIV viral load was measured by real time PCR assay (Abbott). All variables were statistically compared in the two groups.

resultsThe median age was 51 ± 35 months for the HIV group and 50 ± 36 months (p > 0.05) for the control group. Female represented 63% and 41% (p = 0.01), among the HIV group and the control group, respectively. Among HIV-infected children, 71.4% (35/49) were under HAART therapy at the enrollment in the study. Seroprotection titer i.e. anti-HBs ≥10mUI/ml among control group was 76% (85/112), and only 29% (14/49) among the perinatally HIV-infected children (p < 0.0001). Lower % of CD4 + T cells was observed in HIV-infected children with a poor anti-HBs response.

conclusionIn this studied group, we have shown that despite the vaccination of HIV-children with HBV vaccine, 71% did not show any seroprotective response. These findings support the need for monitoring HBV vaccine response among HIV-infected children in Morocco, in order to revaccinate non-immunized children.

Indexed as

Antiretroviral Therapy, Highly ActiveCase-Control StudiesChildChild, PreschoolCoinfectionEnzyme-Linked Immunosorbent AssayFemaleHepatitis BHepatitis B AntibodiesHepatitis B VaccinesHIV InfectionsHumansImmunization ScheduleInfantMaleMoroccoHepatitis B AntibodiesHepatitis B VaccinesHBV vaccineHIV-infected childrenMoroccoSeroprotection

Identifiers

PMID28962610
PMCPMC5622525
OpenAlexW2759392100

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.